COMP <GO>
PTGX vs CORT // 10Y YIELD & FRED MACRO BETA
Protagonist Therapeutics Inc. (NASDAQ) VS. Corcept Therapeutics Incorporated (NASDAQ) • 15-METRIC TALLY: PTGX 4
— CORT 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: PTGX
LAST: $139.37 (-3.78%) • MKT CAP: $9.37B
macro-sensitivity
0.99
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
macro-sensitivity
0.88
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. CORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | CORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | 4.80% | -21.50 | CORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | 1.53% | -0.93 | CORT | /fcf-yield <GO> |
| Operating Margin | -6.00% | 5.90% | -11.90 | CORT | /operating-margins <GO> |
| Net Profit Margin | -5.00% | 13.10% | -18.10 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 12.80% | -12.80 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 27.6 | +30.10 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.99 | 0.88 | +0.11 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 78.3x | -47.30 | PTGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.37B | $8.77B | $604.1M | PTGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | CORT REV | PTGX GROSS % | CORT GROSS % | PTGX FCF | CORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $442.8M | $761.4M | — | 98.3% | $56.1M | $141.8M |
| FY 2024 | $708.0M | $675.0M | — | 98.4% | $182.8M | $196.1M |
| FY 2023 | $262.2M | $482.4M | — | — | -$70.2M | $105.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
CORT // BETA 0.88